David M G Halpin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8143113/publications.pdf

Version: 2024-02-01

72 papers	8,419 citations	201674 27 h-index	102487 66 g-index
73 all docs	73 docs citations	73 times ranked	10084 citing authors

#	Article	IF	Citations
1	Measuring Peak Inspiratory Flow in Patients with Chronic Obstructive Pulmonary Disease. International Journal of COPD, 2022, Volume 17, 79-92.	2.3	8
2	A Systematic Review of Published Algorithms for Selecting an Inhaled Delivery System in Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2022, 19, 1213-1220.	3.2	10
3	Best Practice Management of Patients With Chronic Obstructive Pulmonary Disease: A Case-Based Review. Journal for Nurse Practitioners, 2022, , .	0.8	0
4	Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 17-24.	5.6	57
5	Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis. Advances in Therapy, 2022, 39, 3957-3978.	2.9	10
6	Reducing the hidden burden of severe asthma: recognition and referrals from primary practice. Journal of Asthma, 2021, 58, 849-854.	1.7	8
7	Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 24-36.	5.6	417
8	Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial. Pulmonary Therapy, 2021, 7, 101-118.	2.2	6
9	From GOLD 0 to Pre-COPD. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 414-423.	5.6	119
10	Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD. International Journal of COPD, 2021, Volume 16, 499-517.	2.3	17
11	Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet, The, 2021, 397, 928-940.	13.7	176
12	COPD & COVID-19. Archivos De Bronconeumologia, 2021, 57, 162-164.	0.8	6
13	COPD & COVID-19. Archivos De Bronconeumologia, 2021, 57, 162-164.	0.8	11
14	InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations. Respiratory Research, 2021, 22, 130.	3.6	9
15	INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice. ERJ Open Research, 2021, 7, 00950-2020.	2.6	35
16	Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT. Annals of the American Thoracic Society, 2021, 18, 788-798.	3.2	19
17	Maximizing Adherence and Gaining New Information For Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical Outcomes. Journal of Pragmatic and Observational Research, 2021, Volume 12, 25-35.	1.5	5
18	Peak Inspiratory Flow as a Predictive Therapeutic Biomarker in COPD. Chest, 2021, 160, 491-498.	0.8	10

#	Article	IF	Citations
19	Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care Patient Population Including Both Tested and Untested Patients. Journal of Pragmatic and Observational Research, 2021, Volume 12, 93-104.	1.5	32
20	COVID-19 and COPD: lessons beyond the pandemic. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L978-L982.	2.9	7
21	Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying?. Lancet Respiratory Medicine,the, 2020, 8, 1065-1066.	10.7	24
22	Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. Respiratory Research, 2020, 21, 177.	3.6	13
23	Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study. Advances in Therapy, 2020, 37, 3775-3790.	2.9	9
24	A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD . International Journal of COPD, 2020, Volume 15, 3093-3103.	2.3	0
25	Impact of comorbid conditions on asthmatic adults and children. Npj Primary Care Respiratory Medicine, 2020, 30, 36.	2.6	40
26	Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. European Respiratory Journal, 2020, 55, 2001009.	6.7	227
27	Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial. Respiratory Research, 2020, 21, 139.	3.6	9
28	Comparative Responses in Lung Function Measurements with Tiotropium in Adolescents and Adults, and Across Asthma Severities: A Post Hoc Analysis. Pulmonary Therapy, 2020, 6, 131-140.	2.2	2
29	Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1508-1516.	5.6	151
30	The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1237-1243.	5.6	28
31	Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?. Lancet Respiratory Medicine,the, 2020, 8, 436-438.	10.7	314
32	Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV1. Respiratory Research, 2019, 20, 159.	3.6	15
33	Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respiratory Medicine,the, 2019, 7, 745-756.	10.7	159
34	Exercise and pulmonary rehabilitation for people with chronic lung disease in LMICs: challenges and opportunities. Lancet Respiratory Medicine,the, 2019, 7, 1002-1004.	10.7	29
35	Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations. Clinical and Translational Allergy, 2019, 9, 41.	3.2	46
36	Distribution, Temporal Stability and Appropriateness of Therapy of Patients With COPD in the UK in Relation to GOLD 2019. EClinicalMedicine, 2019, 14, 32-41.	7.1	37

#	Article	IF	Citations
37	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. European Respiratory Journal, 2019, 53, 1900164.	6.7	1,223
38	Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial . International Journal of COPD, 2019, Volume 14, 2681-2695.	2.3	24
39	Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1195-1204.	5.6	94
40	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. Annals of the American Thoracic Society, 2019, 16, 29-39.	3.2	11
41	Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. New England Journal of Medicine, 2018, 378, 1671-1680.	27.0	823
42	Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFTÂ® trial. Respiratory Research, 2018, 19, 196.	3.6	19
43	Understanding irrationality: the key to changing behaviours and improving management of respiratory diseases?. Lancet Respiratory Medicine,the, 2018, 6, 737-739.	10.7	3
44	Inhalation Devices. Canadian Respiratory Journal, 2018, 2018, 1-2.	1.6	5
45	The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease. Tuberculosis and Respiratory Diseases, 2018, 81, 13.	1.8	5
46	Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report. Respirology, 2017, 22, 575-601.	2.3	299
47	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. European Respiratory Journal, 2017, 49, 1700214.	6.7	536
48	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 557-582.	5.6	2,393
49	Impact and prevention of severe exacerbations of COPD: a review of the evidence. International Journal of COPD, 2017, Volume 12, 2891-2908.	2.3	162
50	When is dual bronchodilation indicated in COPD?. International Journal of COPD, 2017, Volume 12, 2291-2305.	2.3	16
51	Preference for different relaxation techniques by COPD patients: comparison between six techniques. International Journal of COPD, 2016, Volume 11, 2315-2319.	2.3	16
52	Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. Respiratory Research, 2016, 17, 120.	3.6	45
53	Tiotropium HandiHaler® and Respimat® in COPD: a pooled safety analysis. International Journal of COPD, 2015, 10, 239.	2.3	29
54	Effect of Tiotropium on Outcomes in Patients With COPD, Categorized Using the New GOLD Grading System: Results of the UPLIFTÂ® Randomized Controlled Trial. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2015, 2, 236-251.	0.7	3

#	Article	IF	Citations
55	Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. Lancet Respiratory Medicine,the, 2014, 2, 267-276.	10.7	149
56	The WISDOM of inhaled corticosteroids in COPD. Thorax, 2014, 69, 1071-1072.	5.6	8
57	Frequency of non-asthma GP visits predicts asthma exacerbations: an observational study in general practice. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2012, 21, 405-411.	2.3	11
58	Exacerbation frequency and course of COPD. International Journal of COPD, 2012, 7, 653.	2.3	138
59	Risk of Nonlower Respiratory Serious Adverse Events Following COPD Exacerbations in the 4-year UPLIFTÂ® Trial. Lung, 2011, 189, 261-268.	3.3	64
60	Lessons from the major studies in COPD: problems and pitfalls in translating research evidence into practice. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2010, 19, 170-179.	2.3	14
61	Preventing chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2009, 3, 449-452.	2.5	0
62	Defining Disease Modification in Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2009, 6, 211-225.	1.6	29
63	Uplifting times for COPD. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2008, 17, 197-198.	2.3	1
64	ABCD of the phosphodiesterase family: interaction and differential activity in COPD. International Journal of COPD, 2008, Volume 3, 543-561.	2.3	53
65	Systemic effects of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2007, 1, 75-84.	2.5	10
66	Assessing the severity of COPD. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2006, 15, 78-80.	2.3	5
67	Chronic obstructive pulmonary disease, inflammation and PDE4 inhibitors. British Journal of Hospital Medicine (London, England: 2005), 2006, 67, 370-374.	0.5	0
68	Health Economics of Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2006, 3, 227-233.	3.5	29
69	Chronic Obstructive Pulmonary Disease: The Disease and Its Burden to Society. Proceedings of the American Thoracic Society, 2006, 3, 619-623.	3.5	115
70	Home or surgery based screening for chronic obstructive pulmonary disease (COPD)?. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2001, 10, 30-33.	2.3	3
71	Epidemiology, Healthcare Resource Utilization, and Mortality of Asthma and COPD in COVID-19: A Systematic Literature Review and Meta-Analyses. Journal of Asthma and Allergy, 0, Volume 15, 811-825.	3.4	18
72	Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation. Journal of Asthma and Allergy, 0, Volume 15, 851-854.	3.4	1